By admin 
For years, the intersection of pharmaceutical pricing and federal policy has been a battlefield of rhetoric, but new disclosures found within Securities and Exchange Commission (SEC) filings are finally shedding light on the opaque agreements struck between the Trump administration and the nation’s leading drugmakers. While President Donald J. Trump frequently utilized his bully pulpit to claim that his "most-favored nation" (MFN) policy had fundamentally restructured the economics of healthcare by ensuring the United States would no longer pay more for prescription drugs than other developed nations, the actual legal frameworks governing these deals remained largely shielded from public view. Recent investigative efforts and a deep dive into corporate financial disclosures have revealed that these supposedly transformative agreements were far more limited in scope than the administration suggested, with a critical discovery being that many of these deals were structured to last for a mere three years.
The "most-favored nation" concept, borrowed from international trade law, was designed to link the prices Medicare pays for certain prescription drugs to the lowest prices paid by other wealthy, industrialized nations. For decades, the United States has been an outlier in global pharmaceutical markets, often paying two to three times more for the same medications than countries like Germany, France, or Japan. This discrepancy is largely attributed to the fact that other nations utilize centralized government negotiations and strict price controls, while the U.S. market has historically relied on a fragmented system of private insurers and a federal ban on direct Medicare price negotiations for outpatient drugs. President Trump’s executive orders aimed to bypass these hurdles by mandating that Medicare Part B—which covers drugs administered in a doctor’s office, such as chemotherapy and injectable biologics—would pay a price pegged to an international benchmark.
However, the implementation of this policy was fraught with behind-the-scenes maneuvering. While the administration touted the cooperation of 16 major pharmaceutical companies, the specifics of these "handshake" deals or formal memoranda remained proprietary. The revelation that these agreements are governed by a three-year sunset clause significantly alters the perception of their long-term impact. Rather than a permanent shift in the American pharmaceutical landscape, these deals appear to have been temporary truces, designed perhaps to provide short-term political victories or to stave off more aggressive legislative action during a high-stakes election cycle.
The SEC filings, which require publicly traded companies to disclose "material" information that could affect their stock price or financial health, provide the first concrete evidence of the duration of these commitments. For the 16 companies involved, which include some of the largest players in the global biotech and pharmaceutical sectors, the three-year window suggests a strategic hedging. By agreeing to temporary price constraints or "favored" status, these companies were able to navigate a volatile political environment without committing to a permanent dismantling of their U.S. pricing power. Industry analysts suggest that the three-year timeframe was likely a compromise—long enough for the administration to claim a victory in lowering costs, but short enough for the industry to wait out a potential change in leadership or a shift in the regulatory winds.
To understand the weight of these disclosures, one must examine the broader context of Medicare Part B spending. Medicare Part B expenditures for prescription drugs have skyrocketed over the last decade, driven by the introduction of high-cost specialty drugs and gene therapies. Unlike Medicare Part D, which involves private plans negotiating with manufacturers, Part B has traditionally paid providers based on the Average Sales Price (ASP) plus a fixed percentage markup. This system has long been criticized for creating incentives to use more expensive drugs, as the percentage-based add-on payment increases with the price of the medication. The MFN model was intended to disrupt this "cost-plus" logic by imposing an external ceiling based on international prices.
The pharmaceutical industry’s reaction to the MFN model was one of intense hostility, leading to a flurry of litigation. Trade groups such as the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) argued that the policy constituted an illegal overreach of executive authority. They contended that the Department of Health and Human Services (HHS) had bypassed the mandatory notice-and-comment period required by the Administrative Procedure Act (APA). Furthermore, industry lobbyists argued that pegging U.S. prices to those of "socialized" healthcare systems would stifle innovation and deprive American patients of life-saving research and development. They warned that the revenue lost from MFN pricing would lead to a "hollowing out" of the American biotech sector, which currently leads the world in the discovery of new molecular entities.
Despite this public-facing combativeness, the SEC filings suggest that a subset of the industry was willing to come to the table to negotiate specific, time-limited concessions. These "most-favored nation" deals were often presented by the White House as a voluntary adoption of the MFN principle by the companies themselves. Yet, the lack of transparency regarding the terms—until now—raised questions among health policy experts about what the government might have given up in exchange. If the deals only last three years, the "new path" the President spoke of may be more of a temporary detour.
The three-year duration is particularly significant when considering the lifecycle of a blockbuster drug. Many of the therapies targeted by the MFN policy are biologics with long patent protections and high barriers to entry for biosimilar competitors. A three-year price freeze or benchmark alignment represents only a fraction of the profitable window for these medications. For investors, the disclosure of a three-year term likely served as a relief, signaling that the "worst-case scenario" of permanent, European-style price controls was not yet a reality.
Moreover, the timing of these deals coincided with the COVID-19 pandemic, a period during which the pharmaceutical industry gained significant political capital through the rapid development of vaccines and therapeutics. This leverage likely played a role in the negotiations. The administration needed the cooperation of these companies for Operation Warp Speed, while simultaneously trying to fulfill a campaign promise to lower drug prices. The resulting agreements appear to be a product of this unique tension—a middle ground that allowed for a "most-favored nation" headline without the structural permanence that would have required an act of Congress.
Economists and health policy researchers at institutions like the Kaiser Family Foundation (KFF) and the Brookings Institution have noted that temporary price controls often lead to "price jumping" or strategic shifts in marketing once the controls expire. If the 16 companies involved in these deals only committed to three years, there is a risk that prices could be hiked aggressively at the end of the term to recoup lost revenue. This phenomenon makes the "most-favored nation" deals look less like a systemic fix and more like a budgetary gimmick. Furthermore, because the details were hidden, it remains unclear how many drugs were actually covered under these specific 16 agreements and whether the "most-favored" status applied to the list price, the net price after rebates, or the Medicare reimbursement rate.
The transition from the Trump administration to the Biden administration has further complicated the legacy of these deals. While President Biden initially paused many of his predecessor’s executive orders, the political pressure to address drug pricing only intensified. This eventually led to the passage of the Inflation Reduction Act (IRA) in 2022, which granted Medicare the power to negotiate prices for a select number of high-cost drugs for the first time in history. Unlike the MFN model, which relied on international benchmarking and executive orders, the IRA is a statutory framework with permanent authority. Interestingly, many of the arguments used by the industry against the Trump MFN deals—such as the threat to innovation and the violation of the Fifth Amendment—have been recycled in the ongoing lawsuits against the Biden administration’s IRA negotiations.
The revelation of the three-year term in the SEC filings also highlights the systemic issue of transparency in healthcare "deals." When the executive branch enters into private agreements with multi-billion-dollar corporations regarding public programs like Medicare, the lack of public disclosure prevents accountability. Taxpayers and beneficiaries are left in the dark about the true cost-savings or the potential trade-offs involved. The fact that the public had to wait for corporate financial filings to learn the duration of a flagship national policy underscores the information asymmetry that defines the American healthcare system.
Looking forward, the "most-favored nation" experiment serves as a cautionary tale for future administrations. While the rhetoric of "America First" pricing resonates with a public frustrated by high costs, the execution of such a policy requires more than just executive orders and short-term agreements. It requires a robust legal foundation that can withstand the inevitable judicial challenges from an industry with deep pockets and a vested interest in maintaining the status quo. The SEC filings have pulled back the curtain on the Trump-era deals, revealing a strategy that was perhaps more focused on the optics of the moment than the long-term sustainability of the Medicare trust fund.
As the three-year marks for these various agreements begin to lapse, the healthcare industry will be watching closely to see if the participating companies return to their previous pricing trajectories. If the "most-favored" status disappears as quickly as it was announced, it will confirm the suspicions of critics who viewed the policy as a transient political maneuver. For now, the data suggests that while the Trump administration may have set the country on a "new path," that path was shorter and more precarious than the public was led to believe. The struggle over drug pricing remains a central pillar of American domestic policy, and the hidden details of these 16 agreements serve as a vital piece of the puzzle in understanding how power is brokered between Washington and the pharmaceutical giants of the world.